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Background: The Forkhead (FKH) transcription factor FOXM1 is a key regulator of the cell cycle and is
overexpressed in most types of cancer. FOXM1, similar to other FKH factors, binds to a canonical FKH motif in vitro.
However, genome-wide mapping studies in different cell lines have shown a lack of enrichment of the FKH motif,
suggesting an alternative mode of chromatin recruitment. We have investigated the role of direct versus indirect
DNA binding in FOXM1 recruitment by performing ChIP-seq with wild-type and DNA binding deficient FOXM1.
Results: An in vitro fluorescence polarization assay identified point mutations in the DNA binding domain of
FOXM1 that inhibit binding to a FKH consensus sequence. Cell lines expressing either wild-type or DNA binding
deficient GFP-tagged FOXM1 were used for genome-wide mapping studies comparing the distribution of the DNA
binding deficient protein to the wild-type. This shows that interaction of the FOXM1 DNA binding domain with
target DNA is essential for recruitment. Moreover, analysis of the protein interactome of wild-type versus DNA binding
deficient FOXM1 shows that the reduced recruitment is not due to inhibition of protein-protein interactions.
Conclusions: A functional DNA binding domain is essential for FOXM1 chromatin recruitment. Even in FOXM1
mutants with almost complete loss of binding, the protein-protein interactions and pattern of phosphorylation are
largely unaffected. These results strongly support a model whereby FOXM1 is specifically recruited to chromatin
through co-factor interactions by binding directly to non-canonical DNA sequences.Background
FOXM1 is a member of the Forkhead family of tran-
scription factors and is a master regulator of the cell
cycle [1–3]. There is growing evidence that FOXM1 is
also involved in the regulation of many other cellular
processes through the activation of specific transcrip-
tional pathways. FOXM1 is frequently overexpressed in
cancer [4–6] and is linked with many processes involved
in oncogenesis, such as metastasis [7, 8], cancer stem
cell proliferation [9, 10], and angiogenesis [11, 12]. Dys-
regulated FOXM1 expression is an early initiating event
in cancer [13, 14] and as such it represents a novel
therapeutic target.
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creativecommons.org/publicdomain/zero/1.0/to target sequences in gene promoters [2]. In common
with other members of the Forkhead family, FOXM1
contains a highly conserved DNA binding domain
(DBD) [15], which in vitro binds to DNA sequences con-
taining a canonical FKH motif (RYAAAYA) [16, 17]. In
humans there are over 40 different Forkhead family
members with diverse biological functions [18] and it is
currently unclear how different Forkhead factors are re-
cruited to specific genomic sites to regulate distinctly
different transcriptional responses.
A number of genome-wide studies have mapped
FOXM1 binding to the FKH target motif, while others
have mapped the indirect binding of FOXM1 through its
interaction with B-Myb or LIN9, a component of the
MuvB complex [19]. These studies present conflicting
models of FOXM1 recruitment to chromatin binding
sites. For example, Sadasivam et al. [19] using HeLa
cells, found that the FKH motif was enriched in genomic
sites bound by LIN9 and B-Myb, which were predomin-
antly located within cell cycle promoters. These dataarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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sus and is co-bound by the MuvB complex and B-Myb.
In contrast, Chen et al. [20] found no enrichment of the
FKH consensus at FOXM1 binding sites in U2OS cells.
This latter study identified just 270 sites total, again lo-
cated primarily in promoter regions associated with cell
cycle genes. The majority of these sites overlapped with
the LIN9/B-Myb binding sites uncovered by Sadasivam
et al. [19]. This study suggested an alternative mechan-
ism of FOXM1 recruitment to chromatin whereby
FOXM1 protein directly interacts with the MuvB/B-Myb
complex rather than at FKH sequences. Our previous
ChIP-seq analysis of FOXM1 binding [21] in two breast
cancer cell lines appears to support existence of both
modes of recruitment. For both MCF7 and MDA-MB-
231 cells, while only 35 and 15 % of peaks respectively
contained the FKH consensus motif these were signifi-
cantly enriched over background.
Conventional recruitment of transcription factors to
genomic binding sites is based on a model of direct
binding at high affinity consensus motif sequences in
cis-regulatory regions. However, there are many exam-
ples of non-canonical modes of transcription factor
binding, including tethering, where a transcription factor
is recruited by other protein complexes previously as-
sembled at the DNA target site. For example, genome-
wide binding studies of ERα, have identified sites lacking
an ERE (estrogen response element), in which binding is
mediated by tethering to a large repertoire of pre-
assembled DNA-binding transcription factors including
AP-1 [22]. Another common mechanism that may be
used together or independently of tethering, is the rec-
ognition by a transcription factor of lower affinity non-
consensus binding sites.
Additionally, some transcription factors show different
modes of recruitment to chromatin at specific sub-sets
of genomic binding sites. For example, the ETS family
member ELK1 [23] has two distinct types of binding
modes, either binding redundantly with other ETS fac-
tors at regulatory sites or uniquely to different binding
sites leading to the regulation of different transcriptional
programs. Similarly, ERα was recently shown to have
two modes of binding, one present in shared sites across
multiple cell lines with high-affinity ERE sequences and
the other cell line-specific that is defined by the lack of
ERE consensus motifs and co-occurrence of a distinct
set of transcription factors [24]. A similar mechanism
may also apply to FOXM1 recruitment, thereby explain-
ing the presence of sites without a consensus FKH bind-
ing site. Such alternative mechanisms of transcription
factor recruitment are thought to increase regulatory
flexibility through the recognition of a wider repertoire
of sites mediated by combinations of different sets of
co-factors [22].Deciphering the precise mechanism of FOXM1 re-
cruitment to genomic binding sites is of key importance
to understand how in vivo binding specificity is achieved.
This has become of great interest due to our recent
proof-of-principle for the potential therapeutic of target-
ing the DBD of FOXM1 by small molecules to prevent
chromatin recruitment and transactivation [25, 26], thus
it is important to elucidate which binding sites represent
direct binding versus indirect events. The aim of this
study was to elucidate the details of FOXM1 binding
genome-wide, by exploring the role of direct versus
indirect FOXM1 recruitment and the mechanism of
binding at sites lacking a FKH consensus sequence.
Additionally, we have examined whether unique FOXM1
binding modes are characterized by any distinctive
affinity binding motifs or the presence of specific protein
co-factors.
Results
The FOXM1 DBD is essential for DNA binding in vitro
The Forkhead DBD [27] adopts a structure consisting of
three α helices, three β sheets, and two wings with the
main contact points with the DNA major groove located
in helix H3. Amino acid residues involved in the base-
specific contacts are highly conserved among all Fork-
head members [28]. To investigate the importance of
direct interaction of the FOXM1 DBD with the FKH
consensus on in vitro binding, four highly conserved H3
amino acids were chosen to generate mutations that are
predicted to interfere with DNA binding. (Fig. 1a; H3
residues selected for mutation are indicated with red
box). Four point mutations, N283A, R286A, H287A,
S290A. and one double mutant N283A/H287A (Fig. 1a)
were engineered and used to generate FOXM1 DBD-
GST-tagged proteins.
The DNA binding activity of the wild-type (WT) and
mutated FOXM1 proteins was assessed by fluorescence
polarization (FP) binding assays using a carboxyfluores-
cein (6FAM) -tagged dsDNA oligonucleotide containing
the FKH consensus sequence (5′AAACAAACAAA-
CAATC). Figure 1b shows that all mutations signifi-
cantly decrease the binding affinity compared to the WT
FOXM1 protein. The Kd for WT FOXM1 for the con-
sensus DNA is 1.10 ± 0.02 μM, compared to 3.04 ± 0.10
μM for H287A. For both the N283A and double mutant
(N283A/H287A) binding did not reach saturation (Kd >5
μM). No significant binding was observed for the R286A
or S290A mutants. While double mutation (N283A/
H287A) appeared to show an additive inhibitory effect
compared to either individual mutations, it still was not
as effective as R286A and S290A, which led to complete
loss of DNA binding.
The effect of the mutations in the FOXM1 DBD on
transcriptional activity was next tested using a cell-based
Fig. 1 Mutation of the FOXM1 DBD inhibits DNA binding. a Sequence alignments of the DBD for a number of Forkhead family members with
the secondary structure shown schematically above. The residues used to generate point mutations are outlined in red. (*) conserved amino
acids. H1-3 are α-helices, the orange arrows are β strands, and W1-2 are winged domains. b Plot showing relative change of polarization of a
fluorescently-labeled (6FAM) dsDNA FKH consensus oligonucleotide upon addition of increasing concentrations of GST-FOXM1 WT or mutant
DBD proteins. The FP assay provides a quantitative method and non-disruptive method to determine FOXM1 affinity for target by measuring the
fluorescence polarization signals from the FAM-labeled FKH consensus (see Materials and methods). Data are plotted as % binding and show
mean ± SD of triplicate experiments. (WT Kd = 1.10 ± 0.02 μM, H287A Kd = 3.04 ± 0.10 μM). c Plots showing relative luciferase activity of a 6X
DB-TATA-luciferase reporter in cells transiently transfected with either WT or DBD mutant FOXM1 with the T596A mutation as a positive control.
Data are shown as fold induction of luciferase activity following doxycycline induction. d Plot showing fold induction of a luciferase reporter
containing a 200 bp sequence taken from the CCNB1 promoter following doxycycline induction of WT and mutant FOXM1 expression. Data
represent triplicate experiments ± SD. (*) P <0.05, (**) P <0.01, (***) P <0.001
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erated in the DBD of the full-length FOXM1B protein,
as this isoform is the predominantly overexpressed iso-
form in cancer [4, 29]. Transient transfections were per-
formed using inducible FOXM1B constructs and the level
of transactivation from the FOXM1 DBD mutations com-
pared to WT, following addition of doxycycline. An add-
itional control was performed based on a T596A mutation
in the transactivation domain of FOXM1 that has been
previously shown to reduce transcriptional activity [17].Constructs were co-transfected into HeLa TRex cells with
a firefly luciferase (FLuc) reporter (6xDB) plasmid con-
taining six copies of the FKH consensus sequence (AAA
CAAACAAAC) and a renilla luciferase reporter (RLuc)
plasmid to control for transfection efficiency. Figure 1c
shows that all mutated FOXM1 proteins had a significant
reduction in transcriptional activity compared to the WT
FOXM1B construct (approximately 25-75 % lower), which
had approximately 10-fold activation on induction with
doxycycline.
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transcriptional activity in the context of endogenous
genomic binding sites rather than the 6x FKH consensus
alone, the cell reporter assay was repeated using pro-
moter regions (approximately 200 bp) from known
FOXM1 target genes, CCNB1 and PLK1 [30, 31], neither
of which contain a FKH consensus motif. Following
doxycycline treatment (1 μg/mL), the level of induction
by the FOXM1 WT construct was approximately three-
fold lower for expression driven by both the CCNB1 and
PLK1 reporters than the 6x FKH consensus (Fig. 1d and
Additional file 1: Figure S1). Results for both of these
promoter constructs showed significantly reduced tran-
scriptional activation following doxycycline induction
with three of the FOXM1 DBD mutations compared to
the WT (R286A, H267A, and S290A). The degree of re-
duction was lower compared to the artificial 6xDB, how-
ever the activity of these promoters is not exclusively
regulated by FOXM1, for example CCNB1 expression is
known to be regulated by an NF-Y binding site con-
tained within this 200 bp region [32] and indeed both of
these natural promoter regions have a higher level of
basal activity than the artificial FKH domain leading to
lower levels of induction with doxycycline. In contrast,
there was no significant difference observed when the
assay was performed using the non-FOXM1 responsive
promoters, CYP1B1 and SV40 (Additional file 1: Figure
S1). These results therefore confirm that specific point
mutations in the DBD can reduce the transcriptional ac-
tivity of FOXM1 at an endogenous binding site.
Generation of epitope tagged FOXM1 cell lines for
ChIP-seq
To compare the genome-wide distribution of binding
sites for WT and DBD mutants of FOXM1, we gener-
ated stable cell lines expressing inducible FOXM1B (WT
or DBD mutants) for use in ChIP-seq experiments. The
FOXM1B construct was tagged with an N-terminus GFP
tag to enable ChIP-seq using an anti-GFP antibody to
distinguish the expressed protein from the endogenous
FOXM1. Transient transfection of FOXM1B or a GFP
only control in HeLa TRex cells confirmed efficient in-
duction of protein expression following doxycycline
treatment (1 μg/mL) (Additional file 1: Figure S2A).
ChIP-qPCR was then performed on five FOXM1 target
genes to assess pull-down efficiency using an anti-GFP
antibody. These results showed the enrichment of GFP-
FOXM1 at the target genes with no detectable binding
of GFP alone (Additional file 1: Figure S2B).
The Flp-In system (Invitrogen) was next used to gen-
erate stable cell lines expressing GFP-FOXM1 WT by
the targeted insertion of an expression construct at a
single transcriptionally active genomic site. This system
was utilized to ensure that the WT and mutant FOXM1proteins were expressed at equivalent levels following in-
duction. HEK293Flp-In cells stably expressing the Tet
repressor at high levels were first generated by transfec-
tion of a TetR plasmid under the control of a CMV pro-
moter. These cells were transfected with WT or mutant
FOXM1-GFP plasmids together with Flp recombinase
plasmid to generate inducible cell lines. In the absence
of doxycycline, no detectable expression of the GFP-
FOXM1 protein or transcript was observed (Fig. 2a and
b), while expression was induced after addition of doxy-
cycline at concentrations above 1 ng/mL, giving approxi-
mately 50-fold higher levels of total FOXM1 protein
(1000 ng/mL) compared to the uninduced cells. There
was no significant change in the level of the endogenous
FOXM1 protein or mRNA following overexpression of
the GFP-FOXM1 as shown by western blotting and
qPCR for the FOXM1 UTR [33]. This result contrasts
the hypothesis, proposed by Halasi et al. [33], that
FOXM1 expression is primarily regulated by a positive
auto-regulatory loop. Isoform specific qPCR (Additional
file 1: Figure S3) showed that only GFP-FOXM1B pro-
tein was significantly upregulated following doxycycline
induction.
Doxycycline induction of WT GFP-FOXM1 led to a
small but significant increase in transcript levels for a
number of known FOXM1 target genes as assessed by
qPCR (Fig. 2c). CCNB1 and CDC25B levels increased by
approximately 2.8 fold, while CENPF showed a smaller
increase of approximately 1.3-fold when compared to
the parental HEK293 TetR cell line (negative) and there
was no significant change in levels of PLK1. When ex-
pression is compared before and after the addition of
doxycycline all four genes showed a slight increase in ex-
pression compared to the parental cell line. The generally
low level of induction observed is similar to that described
in other FOXM1 overexpression studies [3, 31].
These results confirm that GFP-tagged WT FOXM1B
recapitulates endogenous FOXM1 recruitment at gen-
omic targets to elicit a transcriptional response. Next,
stable cell lines were generated that express FOXM1
comprising either the R286A or H287A point mutation
to allow comparison of the binding distributions of WT
and DBD mutated FOXM1. These mutations were se-
lected based on the observed changes in the FP binding
data and also in the luciferase activity assays described
earlier (Fig. 1). The level of DBD mutant GFP-FOXM1
was then compared to the WT following doxycycline
induction (1 μg/mL) by western blotting (Fig. 2d) to
confirm similar protein expression levels in all three cell
lines, which is critical for a precise comparison of bind-
ing by ChIP-seq. Sequencing also confirmed that each
cell lines contained the correct mutation in the GFP-
FOXM1 (Additional file 1: Figure S4) and indirect im-
munofluorescence using an anti-GFP antibody showed
Fig. 2 Generation of inducible GFP-FOXM1 expressing HEK293 cell lines. a Western blot showing induction of GFP-FOXM1B expression following
addition of doxycycline for 24 h while levels of endogenous FOXM1 are unchanged. The blot was probed using antibodies for FOXM1 and ACTB.
b Quantitative PCR (qPCR) showing RNA expression levels of total FOXM1 (GFP-FOXM1 and endogenous) and endogenous FOXM1 only (FOXM1-UTR).
c qPCR of FOXM1 target genes transcript levels in GFP-FOXM1 cells treated ± doxycycline for 24 h and expressed relative to the levels in the parent
HEK293 cells (Negative) for each transcript. Data show triplicate experiments ± SEM. d Western blot showing protein levels of GFP-FOXM1 in WT and
mutant cell lines treated ± doxycycline (Dox) at 1 μg/mL for 24 h
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proteins in the majority of cells (Additional file 1:
Figure S5).
GFP-FOXM1 binding recapitulates endogenous FOXM1
binding
To confirm that the genomic distribution of GFP-
FOXM1 expressed protein matched that of endogenous
FOXM1, ChIP-seq data were compared between HEK
239 Flp-In and HEK293 GFP-FOXM1 cells using with a
FOXM1 or GFP antibody, respectively, following induc-
tion with doxycycline (1 μg/mL). In addition, the gen-
omic binding of GFP in GFP-only expressing cells was
tested, this was done by ChIP-qPCR as it was not pos-
sible to generate a sequencing library due to very low
levels of enrichment following pull-down. No enrich-
ment of 10 known FOXM1 binding sites was observed
in the GFP-only expressing cell line compared to the
GFP-FOXM1 WT cells (Additional file 1: Figure S6).
This confirms that binding of GFP-FOXM1 is due to thespecific interaction of FOXM1 with target DNA rather
than non-specific GFP recruitment.
Two biological replicates were performed for both cell
lines and 25–30 million reads were obtained for each
sample (Additional file 1: Table S1) and binding peaks
were called using Model-based Analysis for Chip-Seq
(MACS) [34]. For endogenous FOXM1, 1,390 peaks
were present in both replicates and for GFP-FOXM1
12,418 peaks were identified (Additional file 2), with a
high level of concordance between replicates (approxi-
mately 78 % for FOXM1 and approximately 81 % for
GFP-FOXM1). Comparison of the endogenous FOXM1
and GFP-FOXM1 peak locations (Fig. 3a) showed a high
degree of overlap (approximately 88 %) indicating that
the GFP-FOXM1 protein captures the majority of the
endogenous FOXM1 binding sites. In the endogenous
FOXM1 replicates approximately 50 % more peaks were
called in one sample (3,970 compared to 1,722). When
less stringent parameters were used for peak calling,
using each replicate separately, the number of binding
Fig. 3 (See legend on next page.)
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Fig. 3 GFP-tagged FOXM1 shows a similar genomic distribution to endogenous FOXM1. a Venn diagram showing the overlap between
endogenous FOXM1 and GFP-FOXM1 binding sites in TetR HEK293 cells, using peaks in common in two replicates for each condition. b Motifs
enriched in FOXM1 and GFP-FOXM1. Selected motifs identified in FOXM1 are also found in the GFP-FOXM1 peaks (full list in Additional file 1:
Table S2). P values and percentages in brackets represent the statistical significance and the percentage of peaks for each motif, respectively. Motif
sequences are sorted according to their proportional representation in FOXM1 peaks. c Examples of genomic regions showing three representative
sites in common for endogenous FOXM1 and GFP-FOXM1 binding. d CEAS analysis comparing genomic distribution of endogenous FOXM1 binding
events to GFP-FOXM1 in HEK293 cells
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FOXM1 increased to 3,173 representing approximately
26 % of the total GFP-FOXM1 binding sites. The ap-
proximately 10-fold increase in high confidence peaks
called in the GFP-FOXM1 samples compared to en-
dogenous FOXM1 is possibly due to the higher affinity
of the GFP antibody and the relatively poor performance
of commercial FOXM1 antibodies in ChIP-seq or the in-
creased level of GFP-FOXM1 compared to endogenous
FOXM1 protein in these cell lines.
Motif analysis using MEME (Multiple Em for Motif
Elicitation) [35] of the FOXM1 and GFP-FOXM1 da-
tasets revealed similar sets of enriched sequences sug-
gesting that the presence of the GFP tag does not
significantly affect the binding specificity of FOXM1
(Additional file 1: Table S2). The six highest enriched
motifs (ranked by FDR) in the endogenous FOXM1
pull-down are shown in Fig. 3b and the P values from
the GFP-FOXM1 are shown for comparison. Both sets
contained the FKH motif as well as the CHR and
CCAAT (NFYA) box motifs that have also previously
been shown to be associated with FOXM1 binding
[19, 20]. The percentage of peaks containing the FKH
motif was similar in both sets (approximately 14 %) and
critically when the peaks present only in the GFP-
FOXM1 dataset were analyzed, these also showed a
similar significant enrichment of the FKH motif (1.73E-
152) in approximately 14 % peaks (Additional file 1:
Table S2). Although the FKH motif is enriched, the rela-
tive number of peaks containing the consensus sequences
is lower than that reported for some other transcription
factors such as POU5F1, where approximately 70 %
of peaks match the POU5F1 PWM motif [36]. This
therefore highlights the observation that the majority of
FOXM1 peaks, both in the endogenous and epitope
tagged ChIP-seq, do not contain a consensus FKH motif.
In both the FOXM1 and GFP-FOXM1 datasets, peaks
were identified in the promoter regions of known
FOXM1 target genes including CDK1 [30], FZR1 [20],
and KNSTRN [20] (Fig. 3c), confirming that the GFP tag
does not affect FOXM1 recruitment in vivo. Manual
inspection of some of the unique GFP-FOXM1 peaks
revealed small peaks at the same location in the en-
dogenous FOXM1 dataset. This suggests that additional
peaks present in the GFP-FOXM1 dataset are lowaffinity endogenous sites, in which the endogenous
FOXM1 ChIP-seq shows insufficient enrichment over
the input to be considered significant by the MACS peak
caller (Additional file 1: Figure S7A). Furthermore,
analysis of read counts in all the 12,418 regions iden-
tified as peaks in the GFP-FOXM1 shows high cor-
relation (r = 0.70-0.75) with endogenous FOXM1
ChIP-seq peaks (Additional file 1: Figure S7B). This
indicates that even when the endogenous FOXM1
signal is insufficient to be called as a peak, it still
shows a significant correlation to the GFP-FOXM1
signal and is not present in input controls. This lends fur-
ther weight to our contention that the signal detected by
FOXM1-GFP ChIP-Seq is not spurious.
Comparison of the distribution of peaks across the
genome using the Cis-regulatory Element Annotation
System (CEAS) tool [37] also shows a very similar pat-
tern between endogenous FOXM1 and GFP-FOXM1
(Fig. 3d), with the greatest proportion in promoter/5′
UTR regions (approximately 53 % and approximately
56 % for GFP-FOXM1 and endogenous FOXM1 re-
spectively compared with 2.8 % for the genome average
distribution). Furthermore, peaks present only in the
GFP-FOXM1 and not the endogenous FOXM1 pull-
down, showed a similar genomic distribution to the en-
dogenous FOXM1, with the majority of events found
in gene promoter regions. The reproducibility, distri-
bution, and motif analysis of the additional peaks
present in the GFP-FOXM1 pull-down strongly sug-
gests that these are not non-specific and are genuine
endogenous FOXM1 sites, which are beyond the
level detectable with the FOXM1 antibody. A similar
phenomenon has been previously observed for other
transcription factors in which improved methodology
using higher affinity antibodies leads to an increased
number of binding sites.
Gene ontology analysis using the Reduce and Visualize
Gene ontology tool (ReViGo) [38] tool of overrepre-
sented GO terms associated with genes located within
50 kb of FOXM1 and GFP-FOXM1 binding peaks high-
lights an enrichment in the known functional roles for
FOXM1 including cell cycle, chromosome segregation
and mitotic spindle formation processes (Additional file 1:
Figure S8). In addition, processes related to methylation
were also identified, which is in concordance with
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thylation [39, 40]. Analysis of enriched GO terms associ-
ated with peaks identified only in the GFP-FOXM1
dataset highlighted processes associated with S phase and
M/G1 transition of the cell cycle, both of which are known
functions of FOXM1 [41, 42] in addition to its major role
in the G2/M transition (Additional file 1: Table S3). This
functional categorization of peaks suggests that that the
GFP-FOXM1 binding pattern reflects that of endogenous
FOXM1.
Overall, these analyses demonstrate that the inducible
GFP-FOXM1 expression system in HEK293 cells is a
suitable model for FOXM1 binding studies. Recruitment
occurs at biologically relevant genomic locations that are
representative of endogenous FOXM1 binding, thus
GFP-FOXM1 expression is able to compete with en-
dogenous FOXM1.
Comparison of genomic binding sites of WT GFP-FOXM1
to DBD mutants
ChIP-seq was next performed to compare the genomic
binding sites of GFP-tagged WT FOXM1 to the two
GFP-tagged DBD mutant versions of FOXM1. Three
biological replicates were performed for the WT and
H287A and two for the R286A cell line. All cells were
treated for 24 h with doxycycline (1 μg/mL) prior to
chromatin extraction.
Each replicate for each cell line resulted in 25–30
million reads (Additional file 1: Table S1). For each
construct, peaks in common between each replicate
showed a good level of concordance. WT, H287A and
R286A replicates showed 7,473 (72 % overlap), 1,169
(60 % overlap) and 804 shared binding events (81 %
overlap), respectively (Additional file 2). Comparing
this GFP-FOXM1 dataset with that in the preceding
section again showed a high level of overlap with
6,443 shared peaks (86 % concordance), further con-
firming the high degree of reproducibility for the GFP-
FOXM1 ChIP-seq. Furthermore, hierarchical clustering
(Fig. 4a) showed that the replicate samples grouped to-
gether indicating a reproducible dataset. Overlapping
the peaks from the WT and DBD FOXM1 mutants
(Fig. 4b) showed that the majority of H287A (86.5 %)
and R286A (98.5 %) peaks are a subset of WT GFP-
FOXM1 binding sites. For H287A, although 156 peaks
did not overlap with the WT or R286A peaks, most
overlapped with at least one WT replicate, suggesting
that they are not novel binding sites. The majority of
R286A peaks are also shared by H287A (approximately
57 %). Of particular note is the observation that both
FOXM1 DBD mutations significantly reduce the over-
all level of genomic binding. The R286A mutation
was more effective at reducing binding compared to
H287A, which is consistent with the in vitro DBD FPanalysis showing that R286A has significantly lower
binding than H287A (Fig. 1c) for the FKH consensus.
To identify any differences in the genomic distribution
of the binding regions, CEAS was used to analyze the lo-
cation of the binding peaks in the WT and DBD FOXM1
mutants (Fig. 4c). Confirming earlier results (Fig. 3d),
the majority of WT FOXM1 peaks were observed to be
in promoter/5′ UTR regions (63.6 % compared to gen-
ome average of 2.8 %). In both the H287A and R286A
mutants, there was an increase in peaks located in the
promoter/5′ UTR regions (66.8 and 81.9 %, respect-
ively), which was more evident in the binding sites com-
mon to both mutants (86 %). These data suggest that
the DBD mutant binding is preferentially retained in
these regions and is also more effectively competed at
other sites by endogenous WT FOXM1 protein. It is
notable that the majority (80–90 %) of WT FOXM1
peaks are almost completely absent in the DBD mutant
binding peaks. Figure 4d shows the ChIP-seq enrich-
ment profiles for WT, R286A and H287A FOXM1 at
three representative known FOXM1 promoter binding
sites with binding peaks only being detected in the WT
sample.
To determine whether any significantly enriched mo-
tifs are present in the peaks where DBD mutant FOXM1
binding is retained, MEME analysis was performed
(Fig. 4e; Additional file 1: Table S4). For WT GFP-
FOXM1, enriched motifs were similar to the earlier
dataset (Fig. 3b) including the FKH and CCAAT box
motifs. When the enriched motifs present uniquely
in the WT GFP-FOXM1 were compared with those
retained in the H287A and H286A mutants, it was
found that the CCAAT box was common to all, while
the FKH motif was only enriched in WT. This con-
firmed that the binding peaks retained in both the
FOXM1 DBD mutants are not regions enriched in
the FKH consensus. Overall, these data indicate that
FOXM1 binding requires a functional DBD but the
targets are in fact quite divergent, encompassing both
canonical FKH and non-consensus DNA sites.
It is striking that genomic sites where DBD mutant
binding is still retained are predominantly those with the
most significantly enriched binding in the WT GFP-
FOXM1 set. For example, 77 % of the joint H287A/
R286A peaks are within the top 1000 FOXM1 WT peaks
(13 % of all FOXM1 WT peaks) ranked by FDR. This
suggests that mutation of key DBD residues ablates
binding to lower affinity sites and that only higher affin-
ity sites are retained with the DBD mutant proteins. This
phenomenon is further illustrated in the heat map in
Fig. 5a, where the average signal intensity for all the
binding events for each protein is shown aligned to the
WT GFP-FOXM1. It can be seen that the highest inten-
sity WT GFP-FOXM1 binding events are preserved in
Fig. 4 (See legend on next page.)
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Fig. 4 Mutation of the DBD of FOXM1 inhibits binding genome-wide. a Hierarchical clustering analysis of the WT and DBD mutant GFP-FOXM1
replicate ChIP-seq datasets showing that the samples separate well into distinct treatment groups. b Venn diagram showing the overlap between
binding regions identified by ChIP-seq analysis in 293 cells expressing GFP-FOXM1 WT and the GFP-FOXM1 mutants H287A or R286A. c CEAS
analysis comparing genomic distribution of GFP-FOXM1 binding events in WT versus DBD mutants. d Examples of genomic regions showing
three representative promoter binding sites in which binding peaks are only identified for GFP-FOXM1 WT and are not present in the DBD
mutant cell lines. e Motifs enriched in WT GFP-FOXM1 and the mutant R286A-H287A (full list in Additional file 1: Table S4). P values and percentages in
brackets represent the statistical significance and the percentage of peaks for each motif, respectively. Motif sequences are sorted according to their
proportional representation in WT GFP-FOXM1 peaks (NS = non-significant)
Sanders et al. Genome Biology  (2015) 16:130 Page 10 of 23both DBD mutant ChIP-seq datasets, although with an
overall loss in the average signal density. We also con-
firmed this observation by ChIP-PCR for three known
promoter binding sites of FOXM1 (Additional file 1:
Figure S9). Figure 5b illustrates three examples of differ-
ential binding of the DBD mutant proteins compared to
the GFP-WT FOXM1 at high-affinity genomic binding
sites.
To investigate whether any particular functional pro-
cesses are associated with binding regions retained in
the mutant DBD FOXM1 samples, the web-based tool
GREAT (Genomic Regions of Enrichment Annota-
tions) [43] was next employed. Output from GREAT
identified a significant enrichment in cell cycle pro-
cesses, particularly those related to M phase control
(Additional file 1: Table S5), which correlates with the
established functions of FOXM1 in cell cycle regula-
tion [2]. A similar analysis on regions bound only by
WT GFP-FOXM1 and not the DBD mutants showed
that there was enrichment of processes associated with
nucleosome organization and chromatin structure,
which is consistent with the identified roles of Fork-
head family members in chromatin remodeling [44].
Enrichment of processes associated with epigenetic
regulation of gene expression was also revealed, which
is consistent with the known link of FOXM1 to the
indirect regulation of methylation through DNMT3b
recruitment [39] or via HELLS expression [40]. Several
other enriched processes related to translation were
also identified in the GFP-FOXM1 WT dataset (Additional
file 1: Table S5).
These data suggest that high affinity FOXM1 binding
sites are retained in the DBD mutants and are associated
with its key functions as a regulator of the cell cycle,
whereas the sites where binding is lost from the DBD
mutants reflect regions associated with other roles such
as chromatin remodeling and epigenetic regulation. The
absence of FKH motif enrichment in the DBD mutants
provides strong evidence for alternative mechanisms of
FOXM1 recruitment possibly mediated by indirect
tethering.
To identify any statistically significant regions of
differential binding between FOXM1 WT and DBDmutants, differential binding analysis (DBA, see Materials
and methods) was performed. For this analysis all
peaks identified in each stable cell line were first used
to generate a consensus dataset containing 18,292
peaks. In the H287A mutant compared to the WT,
11,682 peaks were identified with decreased binding,
and 229 peaks with increased binding (FDR <0.05)
(Fig. 5c and Additional file 3). A similar analysis of
the R286A mutant identified 14,160 regions with de-
creased binding compared to the WT and only five
with increased binding (Fig. 5d and Additional file 3).
No enrichment of biological processes associated with
the 229 peaks with increased binding was found. These
data further confirm that the majority of FOXM1 gen-
omic binding sites are dependent on the presence of a
functional DBD. The R286A mutation, which showed no
discernable DNA binding in the FP assays (Fig. 1b),
showed the greatest reduction in binding, (77 % of peaks
significantly reduced, FDR <0.05). In keeping with the
requirement of the DBD for binding, less peaks (64 %)
showed decreased binding in the H287A mutant, which
is consistent with the residual DNA binding activity
determined by FP.
Overall, our data support the observations of Chen
et al. [20] who also identified a set of FOXM1 binding
sites lacking the FKH consensus motif, where recruit-
ment was mediated through binding to the MuvB com-
plex. However, our study additionally demonstrates that
conserved amino acids of helix H3 in the DBD are none-
theless required for DNA binding even at non-FKH con-
taining sites. For example, Fig. 5a illustrates that binding
intensity is reduced in both DBD mutants compared to
the WT even at highest intensity sites in the WT. Taken
together our observations support two concurrent mech-
anisms for FOXM1 binding: the first being direct inter-
action of FOXM1 with target DNA occurring at the
majority genomic binding sites, and second being recruit-
ment or stabilization by chromatin bound proteins such
as MuvB. As peaks missing in the DBD mutants include
both FKH and divergent motifs, this strongly suggests
that FOXM1 binding does not occur exclusively at
consensus FKH sites. We further discuss these motifs
further below.
Fig. 5 (See legend on next page.)
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Fig. 5 Binding of the GFP-FOXM1 DBD mutants is significantly reduced genome-wide. a Heat map comparing binding events in WT FOXM1 and
both FOXM1 DBD mutants. The window represents ± 5 kb regions centered on WT GFP-FOXM1 binding events with a second plot (on right)
showing the average signal intensity of differential bound peaks. b Three examples of genomic regions showing binding peaks where binding is
reduced in the GFP-FOXM1 DBD mutants compared to the WT. (c and d) Differential binding analysis (DBA) was used to identify significantly
(FDR <0.05) differentially bound peaks in the WT GFP-FOXM1 compared to H287A DBD mutant or the R286A DBD mutant GFP-FOXM1 cell lines.
The red dots represent peaks where FOXM1 binding is significantly increased/decreased compared to the WT
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GFP-FOXM1
To investigate whether the reduced DNA binding of the
DBD mutant proteins is due to perturbation of protein-
protein interactions involved in the recruitment, prote-
omic analysis of the FOXM1 interacting proteins was
performed by RIME (Rapid immunoprecipitation mass
spectrometry of endogenous proteins) [45] for both
the WT GFP-FOXM1 and the R286A DBD mutant.
Formaldehyde-fixed chromatin was isolated from
HEK293 cells expressing either GFP only, GFP-FOXM1
WT, or GFP-FOXM1 R286A and immunoprecipitation
was performed with an anti-GFP antibody followed by
LC/MS-MS (Fig. 6), to identify associated proteins. To
eliminate any non-specific interactions with GFP,
which can occur through cross-linking of the GFP to
highly abundant proteins such as keratins and riboso-
mal sub-units, proteins identified in the GFP only ex-
pressing cell line were not considered in the WT or
R286A samples. High confidence interacting proteins
were then identified using the Scaffold proteomic ana-
lysis tool [46], details of the proteins identified are
shown in Additional file 4. In the WT, several proteins
previously shown to interact with FOXM1 were identi-
fied, including components of the MuvB complex [19]
(LIN9, LIN54), B-MYB [47] and PLK1 [30]. Figure 6b
shows the sequence coverage from Scaffold for the top
five high confidence proteins. These results show that
the presence of the GFP epitope tag does not signifi-
cantly affect the interaction of the GFP-FOXM1 fusion
protein with known partners of endogenous FOXM1.
Overlap of proteins identified in the WT and R286A
replicates (identified by unique peptides present in at
least three out of the four samples) revealed 21
common to both, while eight were present in the WT
only and 15 in the R286A mutant (Additional file 1:
Table S6 and Figure S10).
When the highest confidence interacting proteins
identified in the WT were compared with those in the
R286A DBD mutant (Fig. 6c), it was of note that the
FOXM1 DBD mutant was still able to interact with
MuvB components (LIN9, LIN54), PLK1 and B-MYB.
This interaction was further confirmed by co-IP for
GFP-FOXM1 with B-MYB and LIN9 (Fig. 6d). We ob-
served that the general transcription factor TF2B, which
is known to directly interact with FOXM1 [48], wasidentified in all the WT FOXM1 RIME samples, how-
ever for the DBD mutants T2FB was seen in only one of
four replicates of the R286A mutant. It is possible that
the inability of the DBD mutant to bind DNA impairs
the assembly of active transcriptional complexes despite
preserving the direct binding of core FOXM1 interacting
proteins.
In both the WT and DBD mutant RIME samples,
other components of the MuvB complex [19], LIN37
and LIN54 were also identified, albeit at lower confi-
dence (Additional file 1: Table S6). The identification of
these known FOXM1 binding proteins in the R286A
mutant, which show reduced chromatin recruitment,
could be due to interaction with nuclear non-chromatin
bound FOXM1. Other proteins identified include the
serine/threonine phosphatases PPM1G and PP1G; and it
is of note that a subunit of the related phosphatase
PP2A is known to interact with FOXM1 [49], while
PPM1G is thought to have a key role in cell cycle regula-
tion and in the DNA damage response [50]. Analysis of
the biological pathways associated with the WT GFP-
FOXM1 interacting proteins using the GeneGo Meta-
core tool (Additional file 1: Figure S11), showed a range
of processes that correlate with known FOXM1 roles
including cell cycle, DNA damage and nucleosome
assembly.
FOXM1 activity is regulated by a series of CDK-cyclin
mediated phosphorylation steps [17, 51], which are es-
sential for the formation and nuclear localization of the
transcriptionally active protein at the correct stage of
the cell cycle [17, 52]. We therefore compared serine
and threonine phosphorylation modifications present in
both the WT and R286A DBD mutant FOXM1 proteins
isolated by GFP pull down and subjected to RIME. Ana-
lysis using the Proteome Discoverer with the PhosphoRS
algorithm [53] revealed the presence of many previously
described phosphorylation sites that are required for
FOXM1 transactivation (Fig. 6e and f; Additional file 1:
Figure S12 and Table S7; Additional file 5). These
data also show that the R286A mutant protein under-
goes a similar pattern of phosphorylation as the WT
protein. Our analysis identified one of two known PLK1-
mediated serine phosphorylation sites (S715 but not
S724) in the transactivation domain (TAD) of FOXM1
[30]. It is unclear why this phosphorylation event was
only seen in the WT and not the R286A mutant and this
Fig. 6 (See legend on next page.)
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Fig. 6 Proteomic analysis shows that the FOXM1 DBD mutants bind to same proteins as the WT. a Schematic diagram showing RIME analysis to
identify FOXM1 co-binding proteins. b Coverage of GFP-FOXM1 and associated high-confidence interacting proteins. Yellow shading indicates
regions of peptide coverage and the green shading shows post-translational modifications identified. (Prob = probability, # pep = number of
peptides, %Cov = % protein coverage). c Table showing the average number of peptides identified for the six top proteins present in the WT
GFP-FOXM1 pull-downs. d Co-immunoprecipitation showing pull-down of B-MYB, LIN9, and TF2B with a GFP antibody in extracts from HEK293
cells expressing WT, H287A, and R286A GFP-FOXM1 DBD mutants and GFP only. e Schematic diagram showing phosphorylation sites identified
by Proteome viewer in a WT GFP-FOXM1 RIME sample. The color indicates the identification probability. f Diagram showing the position of
previously identified phosphorylation sites in FOXM1b (red indicates serine and green threonine residues). The table indicates sites identified from
the RIME analysis in WT and R286A DBD mutant GFP-FOXM1, with novel sites highlighted in green
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has bound chromatin. In addition, this analysis identified
several novel serine phosphorylation sites present in
both WT and mutant FOXM1, including S608 and S680
(Additional file 1: Table S7), however their biological
relevance is unclear at present.
Overall, RIME has confirmed previously known pro-
tein interactions and identified novel FOXM1 protein
interactions and post-translational modifications. The
majority of known and novel phosphorylation marks
were found in both mutant and WT protein, with the
notable exception of PLK1 target S715. Furthermore, the
significant reduction in DNA binding for the R286A mu-
tant protein shown in the ChIP-seq analysis is not due
to this mutation affecting protein-protein interactions or
phosphorylation, as overall similar profiles to the WT
were observed.
FOXM1 DBD mutations inhibit expression of
FOXM1-regulated genes
To investigate the effect of the DBD mutations on
FOXM1-regulated gene expression, qPCR was used to
measure the expression levels of several known target
genes (Fig. 7a). Transcript levels were compared in the
WT and DBD mutant cells (H287A and R286A) between
± doxycycline. The level of GFP-FOXM1B induction was
first measured to ensure comparable expression of the
WT and DBD mutants. Indeed by qPCR, the addition of
doxycycline addition led to an approximately 13-fold in-
crease in GFP-FOXM1 expression in both the WT and
DBD mutant cell lines compared to the non-induced
WT GFP-FOXM1 cells (Fig. 7a). Next, the expression of
seven known FOXM1 target genes was measured;
AURKB, CENPF, KNSTRN, CCNB1, CDC25B, NEK2,
and PLK1. In each case, a significant increase in expres-
sion was observed in the GFP WT-FOXM1 cell line fol-
lowing induction by doxycycline (P <0.05). Although the
relative increase in expression was small (in the range of
1.3-fold for AURKB to 1.8-fold for NEK2), this is in the
context of endogenous FOXM1 and comparable to pre-
vious studies [3, 31]. In contrast, for the R286A DBD
mutant there was no significant difference in transcript
levels following induction, whereas for the H287A DBDmutant, three transcripts (CENPF, CCNB1, and PLK1)
showed no significant change on induction This latter re-
sult may reflect a higher residual level of DNA binding ac-
tivity that is observed in the FP assay and by ChIP-seq
when compared to R286A. This is supported by inspec-
tion of the ChIP-seq data for three transcripts (KNSTRN,
CDC25B, and NEK2) that show different responses in the
H287A compared to the R286A mutant (Additional file 1:
Figure S13). In each case the peak in the promoter region
of the gene is significantly smaller in the R286A sample.
These data show that mutations in the DBD, which
significantly impair the DNA binding interaction of
FOXM1, reduce the induction of downstream target
genes. The reduction in transcription seen in the
R286A DBD mutant correlates with RIME analysis
(Fig. 6c and d) showing a decreased association with
the general transcription factor TF2B, which forms
part of the RNA pol II pre-initiation complex [54]. The
R286A DBD mutant reduces expression to levels seen
in the uninduced cells, which suggests that it is unable
to block the transcription mediated by endogenous
FOXM1 protein binding.
FOXM1 binds to lower affinity consensus sequences
Our ChIP-seq results show that overall FOXM1 binding
is significantly depleted when the DNA binding affinity
is reduced, demonstrating the requirement of a func-
tional DBD. However, only approximately 14 % of the
total binding peaks in the WT FOXM1 contain a canon-
ical FKH consensus sequence suggesting that FOXM1
DBD must also be required for recruitment to non-
consensus motifs. FOXM1 binding to alternative motifs
has also been supported by high-throughput studies
which show that Forkhead factors (including mouse
Foxm1) bound two distinctly different DNA sequence
motifs [55]. Furthermore, when the Systematic Evolution
of Ligands by EXponential Enrichment (SELEX) method
was combined with ChIP-seq, a greater diversity of FKH
binding sites was also identified [56]. To confirm
whether FOXM1 binds directly to non-consensus se-
quences identified by ChIP-seq, FP assays were used to
determine the in vitro binding affinity of GST-FOXM1
for non-canonical DNA sequences (Fig. 7b). Regions
Fig. 7 (See legend on next page.)
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Fig. 7 FOXM1 transcriptional activity requires direct chromatin interaction involving recruitment to non-consensus sequences. a qPCR analysis of
the mRNA transcript levels in GFP-FOXM1 WT or mutant (H287A or R286A) cell lines treated ± doxycycline (1 μg/mL) for 24 h showing the relative
change in the levels of FOXM1B, AURKB, CCNB1, CDC25B, CENPF, and PLK1. In each case the data are normalized to the minus doxycycline control.
b Binding curves measured by fluorescence polarization analysis (assay details in the Materials and methods section), showing binding affinity of
GST-FOXM1B DBD for 16-mer [FAM]dsDNA sequences present in FOXM1 binding peaks from the ChIP-seq dataset compared to the FKH consensus.
The plot shows the fraction bound with increasing protein concentration. The table shows the Kd values ± SD determined for each sequence.
c Illustration of alternative models proposed the recruitment of FOXM1 to chromatin. (1) Direct DNA binding of FOXM1 at promoter sites
containing a FKH consensus motif and interaction with MuvB and B-Myb. (2) FOXM1 is recruited by MuvB complex and does not directly bind
to the DNA. (3) FOXM1 binds directly at non-consensus sequences facilitated by interaction with MuvB and B-Myb. Arrow indicates transcription
start site of target gene. Data representative of triplicate experiments ± SD. (*) P <0.05, (**) P <0.01, (***) P <0.001
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were selected from the ChIP-seq dataset, using se-
quences located at the peak center with partial similarity
to the FKH motif (enriched in A/T bases). Additionally,
a previously reported non-consensus FOXM1 binding
site in TATA box of MYC [57] was included. As ex-
pected the FOXM1B DBD associates with a positive
control FKH consensus sequence in a dose dependent
manner (Kd of 224 ± 45 nM). The FOXM1B DBD also
associates with several non-consensus sequences tested
including CCNB2 (Kd = 436 ± 147 nM), HP1BP3 (Kd =
489 ± 233 nM), and the MYC TATA box (Kd = 177 ± 79
nM), but only weakly with the others such as PLK1
where a Kd value could not be determined. Similar re-
sults were observed by Electrophoretic Mobility Shift
Assay (EMSA) (Additional file 1: Figure S14) although
the apparent binding affinities measured were lower (Kd
of 346 ± 24 nM for FKH consensus).
Collectively, these results together with previous in vitro
binding studies [55, 58] demonstrate that FOXM1 can
bind to DNA sequences with significant sequence diver-
gence from the canonical FKH motif. Furthermore, our
results using ChIP-seq and expression analysis with
FOXM1 DBD mutants show that recruitment to non-
consensus sites is also critical for transcriptional activity.
Overall, our data support a mixed model of direct FOXM1
recruitment to chromatin at lower affinity non-consensus
sequences mediated by protein-protein interactions.
Discussion
The aim of this study was to investigate the mechanisms
regulating FOXM1 DNA binding in a cellular context.
FOXM1 has previously been demonstrated to bind to
the FKH consensus motif in vitro. In common with
other Forkhead factors, this interaction is mediated by
the DNA binding domain [57], although with lower af-
finity compared to other FKH factors [59]. Since
FOXM1 has also been suggested to bind at non-FKH
consensus sequences mediated by indirect protein-
protein interactions, we examined the role of direct ver-
sus indirect DNA binding in FOXM1 recruitment using
GFP-tagged FOXM1 expressed in HEK293. Exogenous
expression of a GFP epitope-tagged protein enabled thegeneration of cell lines with specific point mutations in
the DBD of FOXM1 for use in ChIP-seq analysis while
avoiding the known phenotypic responses caused by re-
duced FOXM1 transactivation [60], such as inhibition of
the cell cycle and mitotic catastrophe.
Results for GFP-FOXM1 WT showed that <14 % peaks
contained a consensus FKH motif, which is consistent
with previous results investigating endogenous FOXM1
binding in U2OS cells [20]. However, in contrast to the
prior study, our results provide strong evidence that
DNA recognition by the FOXM1 DBD remains critical
for recruitment to non FKH-consensus genomic binding
sites as opposed to an indirect mechanism mediated
solely by protein-protein interactions. Our results sug-
gest that FOXM1 binding occurs by a process of assisted
recruitment, as proposed by Rabinovich et al. [61] for
the E2F transcription factor, in which most binding sites
lack a consensus motif with binding mediated by add-
itional transcription factors at lower affinity DNA target
sites. Indeed, genome-wide studies have highlighted sev-
eral transcription factors that show low enrichment of
the consensus sequence in their binding sites [61], sug-
gesting that this model of assisted recruitment is a more
general mechanism of transcription factor binding.
Two models previously proposed for the assembly of
FOXM1 with the MuvB complex and B-Myb protein on
cell cycle-regulating promoters are shown in Fig. 7c. The
first (1) shows FOXM1 binding to FKH consensus se-
quences in concert with recruitment of the MuvB com-
plex present at cell cycle homology (CHR) sequences and
B-Myb bound at a MYB binding site in close proximity
[19]. In the second (2), FOXM1 is indirectly recruited by
the MuvB complex at CHR sites together with B-Myb,
without contribution of DBD-DNA interactions [20]. A
third model (3) that is inferred by our results shows an
alternative, mixed mode for FOXM1 recruitment. This
mechanism involves a degree of DNA binding at lower af-
finity, non-canonical sites that is also facilitated by
protein-protein interactions. This latter model would
account for the lack of FKH motifs in the peaks enriched
in FOXM1/FOXM1-GFP pull-down, and is supported
by our data showing that mutations of the DBD in
FOXM1 significantly reduce genome-wide binding at both
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either the protein-protein interactions or the phosphoryl-
ation status of FOXM1.
Considering ours and previous biophysical binding
data, it is probable that FOXM1 exhibits some degree of
DNA binding to the consensus FKH motif. Indeed, we
observe that while FOXM1/FOXM1-GFP ChIP-seq re-
veals a majority of peaks at non-FKH motifs, the FKH
motif is still apparent present in a small but significantly
enriched set (14 %, P = 10−144). Future experiments such
as genetic deletion of discrete motifs by CRISPR would
be needed to unambiguously establish which FKH or
other motifs FOXM1 directly associates. Nonetheless,
our data support the previously proposed model 1 as
well as that suggested by model 3, namely that FOXM1
binding in chromatin operates through a mechanism
dependent on a functional DBD assisted by local protein-
protein recruitment regardless of sequence content. In
support of this, mutant FOXM1 is unable to induce trans-
activation of known FOXM1 target genes, all of which
lack a canonical FKH consensus within the FOXM1 bind-
ing site. It is also notable that binding studies with WT
FOXM1 confirmed that the protein additionally binds
non-consensus sequences, further supporting an assisted
model of FOXM1 binding whereby protein recruitment
stabilizes the association.
Besides an additional model of FOXM1 chromatin re-
cruitment, our work has also revealed novel protein-
protein interactions of FOXM1 by use of the RIME
methodology [45]. Newly identified FOXM1-interacting
proteins include two phosphatases, PPM1G and PP1G,
which may act in a similar manner to the PP2A phos-
phatase that regulates FOXM1 activity during the cell
cycle by controlling dephosphorylation to prevent pre-
mature transcriptional activity [49]. The E3 Ubiquitin-
Protein Ligase, UHRF1 was identified in all the WT
GFP-FOXM1 samples. UHRF1 is known to regulate
gene expression and the cell cycle and is overexpressed
in many cancers [62], and it is of note that UHFR1 binds
inverted CCAAT motifs [63] perhaps enabling require-
ment of FOXM1 at these specific genomic binding sites.
The proposed model of assisted recruitment for
FOXM1 (Fig. 7c, 3) could be applied more widely to in-
clude binding sites other than those at cell-cycle related
promoters, particularly at known sites of MuvB complex
and B-Myb binding [19, 20, 47]. This is exemplified by
the binding of FOXM1 in the COX2 promoter, which is
mediated by interaction with the SP1 transcription factor
at the SP1 binding site in the absence of a canonical
FKH motif [64]. This further suggests that binding to
non-consensus sequences at intronic and intergenic sites
could be facilitated by other transcription factors.
The importance of the Forkhead DBD for direct inter-
action with target DNA sites has been shown for anumber of other Forkhead factors, with disease-causing
mutations having been identified in the FKH DBD domain
[65, 66]. Both DBD mutations examined in this study are
known naturally occurring missense mutations associated
with the loss-of-function of the Forkhead factor. For ex-
ample, the R553H mutation in FOXP2 (equivalent to
FOXM1 R286) is associated with development of a severe
speech language disorder [67], while a mutation of the
same arginine residue in FOXC2 (R121C) is associated
with a developmental disorder affecting the lymphatic vas-
culature system. In the case of FOXM1, the fact that no
similar disease-causing mutations have been associated
with the DBD supports the critical importance of direct
DNA binding for FOXM1 function as are likely to com-
promise cell viability. Indeed, Korver et al. [41], suggests
that any loss-of-function mutations in the FOXM1 DBD
would be embryonic lethal and therefore are not repre-
sented within the general population.
In fact, it is overexpression of WT FOXM1 that is asso-
ciated with disease. In many human cancers FOXM1 over-
expression promotes aberrant activation of FOXM1 target
genes, contributing to oncogenesis and facilitating inva-
sion, metastasis, and therapeutic resistance [6]. Evidence
from this study along with results from our previous work
[25, 26], showing inhibition of FOXM1 DNA binding by
direct interaction with both a small molecule, FDI6 and
with the natural product thiostrepton, suggests that target-
ing the DNA binding domain of FOXM1 might provide a
particularly effective means to ameliorate such a disease
phenotype. We are currently developing chemical tools to
test this hypothesis in future experiments.
Conclusions
Overall, we have demonstrated that the DNA binding
domain of FOXM1, in common with other Forkhead
factors is necessary for recruitment to DNA at consen-
sus and non-consensus FKH genomic binding sites and
activation of down-stream transcriptional activation.
Furthermore, we found that FOXM1 DBD mutants are
unable to bind DNA yet maintain similar protein-
protein interactions to the WT protein. Finally, we iden-
tified novel FOXM1 phosphorylation sites and found
that the majority of all phosphorylation events are un-
affected by DBD mutation. The mechanism of inter-
action of FOXM1 with DNA is of critical importance to
support any development of novel therapeutics designed
to specifically target the DBD of FOXM1, and thereby
reducing transactivation of FOXM1-regulated genes
caused by overexpression in cancer.
Materials and methods
Cell culture
Human HeLa TRex and HEK293 Flp-In cells were
obtained from Invitrogen and grown in EMEM
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mL blasticidin (Sigma) or DMEM supplemented with 10 %
tetracycline free FBS and 100 μg/mL zeocin (Invitrogen),
respectively.
Generation of FOXM1 expressing cell line
The EGFP-FOXM1B fusion plasmid was a gift from
Dr M. Teh (Queen Mary University of London) and
was cloned into the pcDNA4/TO plasmid (Invitrogen)
for transient expression in HeLa TRex cells or into the
pcDNA5FRT (Addgene) to generate stable cell lines.
HEK293 Flp-In cells (Invitrogen) were first transfected
with a pcDNA6/TR plasmid (Invitrogen) and selected
with 5 μg/mL blasticidin to generate a stable HEK293tetR
Flp-In cell line. This cell line was co-transfected with the
GFP-FOXM1 and pOG44 (Flp recombinase vector) and
selected with 100 μg/mL hygromycin (Invitrogen).
Fluorescence polarization assays
Fluorescence polarization (FP) assays were performed to
assess the binding of the FOXM1 mutant DBD compared
to the WT, using a 16mer dsDNA forkhead consensus se-
quence (AAACAAACAAACAATC) labeled with carboxy-
fluorescein at the 5′ position on one strand. Assays were
performed with serial dilutions of DBD proteins from 5
μM to 80 nM in FP-binding buffer (50 mM Tris–HCl pH
7.5, 5 mM MgCl2, 1 mM DTT, and 2 % glycerol). Fluores-
cence was measured using 485 nm excitation and 520 nm
emission filters. Binding plots were generating after ex-
pressing the data as the fraction bound over protein con-
centration, with fraction bound defined as:
% bound ¼ P−P0
P100−P0
(Where P0 is the polarization value at 0 % saturation,
P100 is the polarization value at 100 % saturation, and P
is the observed fluorescence polarization (FP) at each
concentration point.)
Luciferase reporter assays
The pGL4.26 plasmid (Promega) containing a minimum
promoter upstream of the firefly luciferase gene was
used to generate a reporter containing six copies of the
FKH binding consensus as described by Major et al.
[17]. For the 6X FKH consensus, a dsDNA sequence
containing 72 bp with 5′ phosphate groups was ordered
from IDT (Integrated DNA technologies). For the CCNB1
and PLK1 reporters, 200 bp sequences from the CCNB1
and PLK1 promoters were synthesized and inserted into
the promoter-less pGL3 luciferase vector (Promega).
Sanger sequencing was performed commercially to con-
firm the constructs (ATGC Inc.). The renilla control plas-
mid, pRL-TKL, (Promega) was used to normalize fortransfection efficiency. Luciferase assays were performed
using the Dual Luciferase Kit (Promega) as described by
the manufacturer. Briefly, HeLa TRex cells were plated
at 2 × 104 cells/well in 96 well plates in antibiotic free
media containing 10 % tetracycline free FCS and cultured
overnight. Transfections were performed using lipofecta-
mine 2000 following the manufacturer’s protocol. For each
pcDNA4/TO pEGFP FOXM1 construct replicates of 10
were prepared; each transfection contained: 50 ng/well
pEGFP-FOXM1, 50 ng/well pGL4.26 (6XBD), or pGL3
CCNB1/PLK1 and 10 ng/well pRL-TK. Plates were cul-
tured overnight, then for each condition, five wells had
100 μL culture media added and five had media plus
doxycycline (2 μg/mL). These were incubated for an add-
itional 24 h period. Luciferase activity was measured using
the Dual Luciferase Kit (Promega). Luminescence readings
were taken after the addition of each reagent and relative
activity calculated by obtaining the ratio of firefly lucifer-
ase to renilla to account for transfection efficiency, then
the ratio of plus doxycycline to minus to give the relative
induction. Four independent experiments were run with
five replicates for each condition. The control non-
FOXM1 responsive promoter for SV40 in pGL4.10 was
obtained from Promega and the human CYP1B1 pro-
moter was cloned from human gDNA using primers con-






The PCR product was digested and ligated into the
pGL4.10 vector (Promega).
Western blots
Western blots were performed using antibodies for anti-
FOXM1 (sc-502) and anti-HA (sc-543) and anti-β-actin
(ab6276) purchased from Abcam. Fluorescent imaging of
GFP-FOXM1 was performed using an anti-GFP antibody
(ab290) purchased from Abcam. Cell lysates were pre-
pared using RIPA buffer (20 mM Tris–HCl, pH 7.5, 150
mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1 % NP-40, 1
% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1
mM ß-glycerophosphate, 1 mM Na3VO4) with prote-
asome inhibitors (Roche). Lysate was agitated for 30 min
at 4 °C by end-to-end rotation, supernatant collected
following centrifugation (13,000 rpm, 4 °C, 10 min) and
protein concentration measured by BCA (Pierce) assay.
Samples loaded onto 4–12 % Tris-Glycine mini gels
(Invitrogen), purified by SDS-PAGE and transferred to
nitrocellulose membrane (Invitrogen). Membranes were
incubated in Odyssey blocking buffer (LiCor) for 1 h at
























































MYC P2 TATA box [6FAM]TGAGTATAAAAGCCGG CCGGCTTTTATACTCA
CDK1 [6FAM]GCTGCTTTGAAAGTCT AGACTTTCAAAGCAGC
ds[6FAM] sequences used for FP and EMSA analysis
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antibody 1:1,000 and β-actin 1:5,000 overnight at 4 °C. For
detection, the blot was incubated with LiCor IRDye sec-
ondary antibodies; 680LT goat anti-rabbit IgG and 800LT
goat anti-mouse IgG both at 1:10,000 and visualized using
an Odyssey scanner.
Immunofluorescence
Cells were plated 4 × 104/well in Ibidi treated 8-well cul-
ture slides (Ibidi) and left to adhere overnight. Following
doxycycline treatment for 24 h the cells were washed 1X
with PBS and fixed with 4 % methanol-free formalde-
hyde at room temperature for 15 min. After washing 3X
with PBS, cells were permeabilized and blocked using
blocking buffer (PBS/5 % normal goat serum/0.3 %
Triton-X 100) for 1 h at room temperature. GFP anti-
body was diluted in antibody blocking buffer (PBS/1 %
BSA/0.3 % Triton-X 100) FOXM1 (1:500) and added to
appropriate wells leaving control wells with buffer only.
Culture wells were incubated at 4 °C overnight followed
by washing 3X with PBS. Secondary antibodies were di-
luted 1:2,000 in antibody dilution buffer, using either goat
anti-Rabbit Alexa Fluor 488 (Invitrogen) and added for
1 h in the dark at room temperature. Culture wells were
washed 3X with PBS, with one wash containing DAPI
(1 μg/mL) for nuclear staining. Liquid was removed
from wells and anti-fade mounting media (Ibidi) added
to each well. Plates were stored in the dark at 4 °C and vi-
sualized using an inverted Leica DMI6000B microscope.
Quantitative real-time PCR analysis
RNA was collected after the indicated time-points and
qPCR was performed using Power Sybr mix (ABI) on a
CFX96 Real-time thermal cycler (Bio-Rad). Total RNA
was extracted using the RNeasy mini kit (Qiagen) fol-
lowing the manufacturer’s protocol. cDNA was prepared
from 1 μg RNA using Maxima reverse transcriptase
(Fermentas) following the manufacturer’s protocol. qPCR
was performed in triplicate in 10 μL reactions with
Power sybr mix (ABI) using Qiagen quantitect primers
for B2M, ACTB, CCNB1, CDC25B, and FOXM1 and
additional primers shown below. ACTB and B2M were
used as housekeeping genes for normalization of the
data. PCR conditions were: 95 °C 10 min, 40 cycles of
95 °C for 15 s, and 60 °C for 30 s followed by a dis-
sociation curve (60–95 °C). Relative expression levels
were calculated using the delta delta CT method [68].
Chromatin immunoprecipitation
ChIP experiments were performed as previously described
[69] using the following antibodies: anti-FOXM1:Genetex
(GTX1000276), Genetex (GTX102170), and anti-GFP
(Abcam ab-290). Experimental details and primer se-
quences are listed below.Primer sequences:
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Initial ChIP-Seq experiments were performed using
two biological replicates for both endogenous and
GFP-tagged FOXM1 in HEK293 cells. To analyze the
WT GFP-FOXM1 versus DBD mutants, three repli-
cates were performed for the WT and H287A and two
for the R286A HEK293 stable cell lines (Additional
file 1: Table S1). ChIP DNA was processed for
Illumina sequencing as previously described [69].
Further details are given in Additional file 3. Data
are available through the NCBI’s Gene Expression
Omnibus [70] using GEO Series accession number
GSE60032. Single end 36-bp ChIP-seq data were gen-
erated by the Illumina analysis pipeline CASAVA 1.7
and OLB 1.9.4. Reads were aligned to the Human
Reference Genome (assembly hg19, NCBI Build 37,
February 2009) using bwa 0.6.1 [71] with default
settings and reads that could not be confidently
assigned to a unique genome position (that is, with
mapping quality mapq <15) were removed (Additional
file 1: Table S1). In addition, reads overlapping re-
gions known to accumulate unusually large number
of reads in a non-specific manner were excluded
(excluded regions obtained from [72]). Read-enriched
regions (that is, binding sites) were identified with
MACS 1.4.1 [34] using as control file a genomic
input prepared from the same cell lines as the ChIP
libraries.
RIME analysis
RIME analysis was performed as previously described
[45] using the anti-GFP antibody (ab290, Abcam).
Samples were processed for LC/MS-MS and analyzed
by the Proteomics Core facility at the CRUK Cam-
bridge Research Institute. The RIME protocol (Rapid Im-
munoprecipitation Mass Spectrometry of Endogenous
proteins) developed by Mohammed and Carroll [73] was
used to identify FOXM1 interacting proteins. Preparation
of nuclear fraction is similar to that described for ChIP
samples in with minor modification: cells from 4 × 15 cm2
dishes were cross-linked using 1 % methanol-free formal-
dehyde (Pierce) for 7 min and quenched with 2.5 M gly-
cine (final concentration 0.2 M). After scraping the plates
the cells were combined a 15 mL tube and lysed with 10
mL LB1, 10 mL LB2, then resuspended in 1,200 μL LB3
and split into 4 × 1.5 mL tubes for sonication. Protein G
Dynal beads (Invitrogen) were used for the IP and after
overnight incubation with the cleared lysate the beads
were washed 10X with RIPA buffer followed by 2X
with 100 mM ammonium hydrogen carbonate solu-
tion. Following the first wash, the beads were trans-
ferred to new tubes. Antibody used for pull-down was
GFP (Abcam; ab290). Experiments were performed in
triplicate.Samples were processed and analyzed by LC-MS/MS
by the proteomics core at the CRUK Cambridge Insti-
tute. In brief, all samples were analyzed using MASCOT
(Matrix Science, London, UK; version 1.3.0.339) and X!
Tandem (The GPM, thegpm.org; version CYCLONE
(2010.12.01.1)) protein identification software. Mascot
was set up to search Mascot5_SwissProt_Homo sapiens
(human) (unknown version, 20,284 entries) assuming
the digestion enzyme trypsin. X! Tandem was set up to
search a subset of the SwissProt_2013_05 database also
assuming trypsin digestion. Mascot and X! Tandem
were searched with a fragment ion mass tolerance of
0.80 Da and a parent ion tolerance of 10.0 PPM. Deami-
dation of asparagine and glutamine and oxidation of
methionine were specified in Mascot as variable modifi-
cations. Glu- > pyro-Glu of the n-terminus, ammonia-
loss of the n-terminus, gln- > pyro-Glu of the n-
terminus, deamidation of asparagine and glutamine and
oxidation of methionine were specified in X! Tandem as
variable modifications.
Protein identifications were accepted if they could be
established at greater than 99.0 % probability based on
the peptide coverage and contained at least one unique
peptide. Protein probabilities were assigned by the Pro-
tein Prophet algorithm [74]. Phosphorylation sites were
identified with Proteome discoverer (Thermo Fisher
Scientific).
Analysis of differential binding
To identify regions of differential FOXM1 binding
between the WT and DBD mutant samples, a gen-
eral linear model was fitted to each putative binding
site to test for the difference in read count between
treatments. Model fitting and testing was performed
using the Bioconductor library edgeR [75] using the
function estimateGLMTagwiseDisp for estimating the
dispersion parameter of the negative binomial distri-
bution and glmFit and glmLRT for fitting and testing
the difference of treatment of each binding site [76].
The heatmaps were prepared with R. Hierarchical
clustering was performed using the hclust package
in R.
Motif analysis and genomic distribution of binding events
The cis-regulatory element annotation system (CEAS)
[37] function in cistrome (http://cistrome.org/ap/) was
used to functionally annotate binding sites. Known
transcription factor motifs significantly enriched in the
binding sites were identified with MEME suite [77].
Transcription factor motifs enriched in the sequences
spanned by the ChIP-Seq peaks have been discovered
with ame program [78]. Transcription factor motifs were
obtained from the JASPAR database included in the
meme suite [79]:
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spanning each ChIP-Seq peak. The significance thresh-
old for motif detection was set to the default value of
0.05.
Percentages for the enriched motifs were calculated by
matching peak sequences to the following regular ex-
pressions, where letters are according to the IUPAC nu-
cleotide code: TTTRAAW (CHR); GGGMGGGR (SP2);
CCAATSR (NFYB); RTAAAYA (FOXP2); AGRDGGCG
(CTCF); YTTCCGG (ELK4).GO pathway analysis
GO pathway enrichment was performed using GeneGo
metacore (MetaCore from Thomson Reuters) and
visualized with REViGO (Reduce and Visualize Gene
Ontology) [38].Co-immunoprecipitation
Experiments were performed using the nuclear co-IP kit
from Active motif with pull-down using a FOXM1 anti-
body (Santa Cruz sc-502) following the manufacturer’s
protocol with immunoprecipitation carried out using the
low buffer provided supplemented with 1X protease in-
hibitor cocktail). Detection was performed by western
blotting using B-Myb (Santa Cruz sc-724), Lin9 (Abcam
ab-71887), and TFIIB (Santa Cruz sc-225) with LiCor
IRDye secondary antibodies (800LT goat anti-mouse,
680LT goat anti-rabbit and 680LT donkey anti-goat).
Cells were harvested at 70 % confluence in 15 cm2
dishes using PBS with phosphatase inhibitors at 4 °C
and spun at 1,500 rpm for 5 min at 4 °C. Nuclear lysates
were prepared by resuspending the cell pellets in 1X
hypotonic buffer and incubating for 15 min on ice,
following detergent addition the supernatant was centri-
fuged at 14,000 ×g for 30 s to pellet the nuclear fraction.
The nuclear fraction was digested using complete diges-
tion buffer with addition of the enzymatic shearing cock-
tail at 4 °C for 2 h with end-to-end rotation. EDTA was
added to give a final concentration of 10 mM and the
cleared supernatant collected following centrifugation at
14,000 ×g for 10 min at 4 °C. Protein concentration was
measured by BCA (Pierce). Immunoprecipitation (IP)
was performed using 400 μg protein per reaction with
either 4 μg FOXM1 antibody (sc-502) or Rabbit IgG
(Cell Signaling) using either the supplied low or high IPbuffer supplemented with X1 protease inhibitor cocktail
and in some samples 1 mM DTT, in a final volume of
500 μL. Incubation was carried out overnight at 4 °C
with end-to-end rotation. Pull-down was performed by
the addition of 50 μL pre-washed protein A magnetic
beads (Invitrogen) for 1 h followed by X6 washes with
IP buffer. After the final wash, beads were collected by
centrifugation and resuspended in 15 μL of X1 Novex
sample buffer (Invitrogen) and heated at 70 °C for 10 min
to release the bound proteins. Western blotting was per-
formed as detailed above using antibodies for: FOXM1
(sc-502) 1:1,000, GFP (ab290) 1:5,000, LIN9 (ab71887),
B-Myb (sc-724) 1:1,000 and TF2B (sc-225) 1:1,000, with
LiCor IRDye secondary antibodies; 680LT goat anti-
rabbit IgG and 800LT goat anti-mouse IgG both at
1:10,000 and 680LT donkey anti-goat IgG at 1:15,000 and
visualized using an Odyssey scanner.
Statistical analysis
All statistical analyses not described above were per-
formed with GraphPad prism software or R [80]. The
tests for difference between means were performed
using the two-tailed Student’s t-test. If not otherwise
stated, P value <0.05 were considered statistically signifi-
cant. Error bars represent standard deviations.
Additional files
Additional file 1: Supplementary Methods, Tables and Figures as
mentioned in the text.
Additional file 2: FOXM1 binding peaks. Excel spreadsheet containing
location of FOXM1 binding peaks identified using MACS in replicate
ChIP-seq experiments performed with endogenous FOXM1 and WT and
DBD mutated GFP-FOXM1 in HEK293 cell lines.
Additional file 3: Differential binding data. Excel spreadsheet with
output from DBA. Differential bound peaks (FDR <0.05) were identified
using edgeR.
Additional file 4: RIME proteomics data. Excel spreadsheet with
details of proteins identified following RIME analysis of FOXM1 interacting
proteins. Experiment was performed using four biological replicates
analyzed in two batches shown on sheets 1 and 2.
Additional file 5: Phosphorylation sites. Excel spreadsheet with details
of phosphorylation sites identified following RIME analysis in four
replicates of WT GFP-FOXM1 or R286A DBD mutant GFP-FOXM1.
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